The investment will support Biorce’s growing demand, international expansion, team growth, and continued development of its AI platform for clinical trials.
Barcelona-based Biorce, a health AI company focused on clinical trial design and execution, has closed a $52 million Series A round. The financing includes new investment from DST Global Partners, with existing investors Norrsken VC and YZR Capital increasing their participation, alongside Mustard Seed Maze. The round also includes angel investors such as Arthur Mensch, Albert Nieto, Paulo Rosado, and Nik Storonsky. Following the round, Biorce’s total funding has surpassed $60 million.
Biorce is developing AI infrastructure to improve how clinical trials are designed and conducted, with its Aika platform at the core. Aika is an AI-native platform designed to reduce clinical trial preparation timelines and limit protocol amendments, supporting faster development of new therapies.
In traditional trial models, protocol amendments often pause patient recruitment for an average of six weeks and can add between €500,000 and €1 million in costs per amendment. These challenges are frequently linked to difficulties in clearly substantiating trial design decisions to regulatory authorities such as the FDA and the EMA, which can lead to extended reviews, delays, and additional amendments.
Pedro Coelho, CEO of Biorce, commented:
Clinical trial delays and inefficiencies cost time, money, and ultimately lives. Our mission is to make trials faster, more reliable, and more accessible, so patients can benefit from new treatments sooner.
Built on a dataset of approximately one million clinical trials, Aika is designed to help anticipate risks, reduce errors, and limit the need for protocol changes. The platform supports pharmaceutical companies, biotech firms, and contract research organisations in designing trials more efficiently while maintaining scientific standards and patient safety.
Aika is already in use across multiple therapeutic areas, including oncology, neurology, and rare diseases. Its therapy-agnostic design allows Biorce to apply AI across a wide range of clinical programmes and scale its approach to clinical trial design and management.
Looking ahead, Biorce plans to expand its workforce and open a development and R&D hub in Austin, Texas, to support its activities in the US.
In early 2026, the team intends to further develop Aika’s protocol intelligence capabilities and introduce additional modules, including tools for contract management, negotiation, budget planning, and operational execution, aimed at improving trial efficiency and patient access to new therapies.